Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients

The aims of this study were to assess hepatitis B surface antigen (HBsAg) seroconversion and to determine its impact on the natural course of the disease in patients with HBeAg‐negative chronic hepatitis B (CHB) during lamivudine (LMV) treatment. A total of 183 consecutive patients with HBeAg‐negati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of viral hepatitis 2012-03, Vol.19 (3), p.220-226
Hauptverfasser:	Idilman, R., Cinar, K., Seven, G., Bozkus, Y., Elhan, A., Bozdayi, M., Yurdaydin, C., Bahar, K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Viral - blood Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use chronic hepatitis B Cirrhosis Data processing DNA DNA, Viral - blood Female Fibrosis - pathology Fibrosis - virology Hepatitis B e Antigens - blood Hepatitis B e Antigens - immunology Hepatitis B surface antigen hepatitis B surface antigen quantification Hepatitis B Surface Antigens - blood Hepatitis B Surface Antigens - immunology Hepatitis B virus Hepatitis B virus - immunology Hepatitis B, Chronic - blood Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Humans Interferon-alpha - therapeutic use Lamivudine Lamivudine - administration & dosage Lamivudine - therapeutic use Male Middle Aged Seroconversion Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!